{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T12:37:46Z","timestamp":1771591066073,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T00:00:00Z","timestamp":1666742400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T00:00:00Z","timestamp":1666742400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatologie"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:sec>\n                <jats:title>Hintergrund<\/jats:title>\n                <jats:p>Ven\u00f6se Ulcera cruris treten in 1\u202f% der Bev\u00f6lkerung in industrialisierten L\u00e4ndern auf. Ihre Behandlung ist schwierig und kostspielig. Eine komplette Abheilung zu erzielen ist langwierig, und die Rezidivrate ist hoch, bis zu 69\u202f% im ersten Jahr nach der Abheilung.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Fragestellung<\/jats:title>\n                <jats:p>In dieser Studie untersuchten wir, ob durch die lokale Therapie der ven\u00f6sen Ulzera mit niedrig dosiertem GM-CSF die Abheilraten verbessert und Rezidive verringert werden k\u00f6nnen.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methoden<\/jats:title>\n                <jats:p>Wir behandelten alle konsekutiven Patienten mit einem chronisch ven\u00f6sen Ulkus lokal mit einer niedrig dosierten GM-CSF-L\u00f6sung (10\u202f\u00b5g\/ml 0,9\u202f%ige Kochsalzl\u00f6sung, entsprechend einer Dosis von1,0\u20132,3\u202f\u00b5g\/cm<jats:sup>2<\/jats:sup> Wundoberfl\u00e4che). Alle Patienten waren \u00fcber mehrere Wochen (median 8\u00a0Wochen) erfolglos mit anderen Lokaltherapien vorbehandelt. Bei allen Patienten erfolgte begleitend eine ad\u00e4quate Therapie der ven\u00f6sen Insuffizienz.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Ergebnisse<\/jats:title>\n                <jats:p>Von 130\u00a0Patienten sind bei 119 (91,5\u202f%) Patienten die Ulzera komplett abgeheilt. Lokale oder systemische Nebenwirkungen wurden nicht beobachtet. Die mittlere Abheilzeit war 24\u00a0Wochen (median 14\u00a0Wochen). Wir konnten alle 119 abgeheilten Patienten nachverfolgen. Die mediane Nachbeobachtungszeit betrug 84\u00a0Monate. Die Rezidivrate betrug nach 1\u00a0Jahr 5,2\u202f%, nach 4\u00a0Jahren 18,9\u202f%, nach 10\u00a0Jahren 32,0\u202f%<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Schlussfolgerung<\/jats:title>\n                <jats:p>Die Behandlung ven\u00f6ser Ulzera mit lokal appliziertem, niedrig dosiertem GM-CSF erwies sich als sichere, hochwirksame und kosteng\u00fcnstige Therapie. Die Abheilrate ist ebenso hoch wie in der ESCHAR Studie (Effects of Surgery and Compression on Healing And Recurrence in venous ulceration), und die Rezidivrate ist niedriger als in der Literatur angegeben. Die GM-CSF-Therapie erfolgte ausschlie\u00dflich ambulant. Es waren keine Spitalaufenthalte notwendig.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00105-022-05068-4","type":"journal-article","created":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T11:03:34Z","timestamp":1666782214000},"page":"41-48","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Lokale Therapie von ven\u00f6sen Ulzera mit niedrig dosiertem rekombinantem, humanem \u201egranulocyte-macrophage colony-stimulating factor\u201c (rhu GM-CSF), 10\u00a0Jahre Nachbeobachtung","Low-dose topical recombinant human granulocyte\u2013macrophage colony-stimulating factor (rhu GM-CSF) therapy for chronic venous leg ulcers, 10-year follow-up"],"prefix":"10.1007","volume":"74","author":[{"given":"Erna","family":"Jaschke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julian","family":"Umlauft","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin","family":"Palmer-Reichel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wilhelm","family":"Oberaigner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Schmuth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,10,26]]},"reference":[{"key":"5068_CR1","doi-asserted-by":"publisher","first-page":"400","DOI":"10.12968\/jowc.1995.4.9.400","volume":"4","author":"F Arnold","year":"1995","unstructured":"Arnold\u00a0F, O\u2019Brien\u00a0J, Cherry\u00a0G (1995) Granulocyte monocyte-colony stimulating factor as an agent for wound healing. J\u00a0Wound Care 4:400\u2013402. https:\/\/doi.org\/10.12968\/jowc.1995.4.9.400","journal-title":"J Wound Care"},{"key":"5068_CR2","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1053\/ejvs.2000.1196","volume":"20","author":"J Barwell","year":"2000","unstructured":"Barwell\u00a0J, Taylor\u00a0M, Deacon\u00a0J, Ghauri\u00a0A, Wakely\u00a0C, Phillips\u00a0L, Whyman\u00a0M, Poskitt\u00a0K (2000) Surgical correction of isolated superficial venous reflux reduces long-term recurrence rate in chronic venous leg ulcers. Eur J Vasc Endovasc Surg 20:363\u2013368. https:\/\/doi.org\/10.1053\/ejvs.2000.1196","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"5068_CR3","first-page":"61","volume":"32","author":"H Brem","year":"2018","unstructured":"Brem\u00a0H, Howell\u00a0R, Criscitelli\u00a0T, Senderowicz\u00a0A, Siegart\u00a0N, Gorenstein\u00a0S, Gillette\u00a0B (2018) Practical application of granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with wounds. Surg Technol Int 32:61\u201366","journal-title":"Surg Technol Int"},{"key":"5068_CR4","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.4238\/2015.March.31.3","volume":"14","author":"YF Chi","year":"2015","unstructured":"Chi\u00a0YF, Chai\u00a0JK, Luo\u00a0HM, Zhang\u00a0QX, Feng\u00a0R (2015) Safety of recombinant human granulocyte-macrophage colony-stimulating factor in healing pediatric severe burns. Genet Mol Res 14:2735\u20132741. https:\/\/doi.org\/10.4238\/2015.March.31.3","journal-title":"Genet Mol Res"},{"key":"5068_CR5","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1046\/j.1524-475x.1999.00017.x","volume":"7","author":"RM Da Costa","year":"1999","unstructured":"Da Costa\u00a0RM, Jesus\u00a0FMR, Aniceto\u00a0C, Mendes\u00a0M (1999) Randomized, double-blind, placebo-controlled, dose-ranging study of granulocyte-macrophage colony stimulating factor in patients with chronic venous leg ulcers. Wound Repair Regen 7:17\u201325. https:\/\/doi.org\/10.1046\/j.1524-475x.1999.00017.x","journal-title":"Wound Repair Regen"},{"key":"5068_CR6","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1111\/ddg.12351","volume":"12","author":"J Dissemond","year":"2014","unstructured":"Dissemond\u00a0J, Augustin\u00a0M, Eming\u00a0SA, Goerge\u00a0T, Horn\u00a0T, Karrer\u00a0S, Schumann\u00a0H, St\u00fccker\u00a0M (2014) Modern wound care\u2014practical aspects of non-interventional topical treatment of patients with chronic wounds. J\u00a0Dtsch Dermatol Ges 12:541\u2013554. https:\/\/doi.org\/10.1111\/ddg.12351","journal-title":"J Dtsch Dermatol Ges"},{"key":"5068_CR7","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1111\/j.1365-2133.2007.07979.x","volume":"157","author":"Y Fang","year":"2007","unstructured":"Fang\u00a0Y, Gong\u00a0S\u2011J, Xu\u00a0Y\u2011H, d Hambly\u00a0B, Bao\u00a0S (2007) Impaired cutaneous wound healing in granulocyte\/ macrophage colony-stimulating factor knockout mice. Br J Dermatol 157:458\u2013465. https:\/\/doi.org\/10.1111\/j.1365-2133.2007.07979.x","journal-title":"Br J Dermatol"},{"key":"5068_CR8","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1177\/0268355514568848","volume":"30","author":"W van Gent","year":"2015","unstructured":"van Gent\u00a0W, Catarinella\u00a0F, Lam\u00a0Y, Nieman\u00a0F, Toonder\u00a0I, van der Ham\u00a0A, Wittens\u00a0C (2015) Conservative versus surgical treatment of venous leg ulcers: 10-year follow up of a\u00a0randomized, multicenter trial. Phlebology 30:35\u201341. https:\/\/doi.org\/10.1177\/0268355514568848","journal-title":"Phlebology"},{"key":"5068_CR9","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1136\/bmj.39216.542442.BE","volume":"335","author":"MS Gohel","year":"2007","unstructured":"Gohel\u00a0MS, Barwell\u00a0JR, Taylor\u00a0M, Chant\u00a0T, Foy\u00a0C, Earnshaw\u00a0JJ, Heather\u00a0BP, Mitchell\u00a0DC, Whyman\u00a0MR, Poskitt\u00a0KR (2007) Long term results of compression therapy alone versus compression plus surgery in chronic venous ulceration (ESCHAR): randomised controlled trial. BMJ 335:83. https:\/\/doi.org\/10.1136\/bmj.39216.542442.BE","journal-title":"BMJ"},{"key":"5068_CR10","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/j.1365-2133.1995.tb08629.x","volume":"132","author":"HR Higley","year":"1995","unstructured":"Higley\u00a0HR, Ksander\u00a0GA, Gerhardt\u00a0CO, Falanga\u00a0V (1995) Extravasation of macromolecules and possible trapping of transforming growth factor\u2011\u03b2 in venous ulceration. Br J Dermatol 132:79\u201385. https:\/\/doi.org\/10.1111\/j.1365-2133.1995.tb08629.x","journal-title":"Br J Dermatol"},{"key":"5068_CR11","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.burns.2010.08.016","volume":"37","author":"X Hu","year":"2011","unstructured":"Hu\u00a0X, Sun\u00a0H, Han\u00a0C, Wang\u00a0X, Yu\u00a0W (2011) Topically applied rhGM-CSF for the wound healing: a systematic review. Burns 37:729\u2013741. https:\/\/doi.org\/10.1016\/j.burns.2010.08.016","journal-title":"Burns"},{"key":"5068_CR12","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1046\/j.1365-4362.1999.00665.x","volume":"38","author":"E Jaschke","year":"1999","unstructured":"Jaschke\u00a0E, Zabernigg\u00a0A, Gattringer\u00a0C (1999) Recombinant human granulocyte-macrophage colony-stimulating factor applied locally in low doses enhances healing and prevents recurrence of chronic venous ulcers. Int J Dermatol 38:380\u2013386. https:\/\/doi.org\/10.1046\/j.1365-4362.1999.00665.x","journal-title":"Int J Dermatol"},{"key":"5068_CR13","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1046\/j.0022-202x.2001.01600.x","volume":"117","author":"A Mann","year":"2001","unstructured":"Mann\u00a0A, Breuhahn\u00a0K, Schirmacher\u00a0P, Blessing\u00a0M (2001) Keratinocyte-derived granulocyte-macrophage colony stimulating factor accelerates wound healing: Stimulation of keratinocyte proliferation, granulation tissue formation, and vascularization. J\u00a0Invest Dermatol 117:1382\u20131390. https:\/\/doi.org\/10.1046\/j.0022-202x.2001.01600.x","journal-title":"J Invest Dermatol"},{"key":"5068_CR14","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/sj.jidsymp.5650013","volume":"11","author":"A Mann","year":"2006","unstructured":"Mann\u00a0A, Niekisch\u00a0K, Schirmacher\u00a0P, Blessing\u00a0M (2006) Granulocyte\u2013macrophage colony-stimulating factor is essential for normal wound healing. J\u00a0Investig Dermatol Symp Proc 11:87\u201392. https:\/\/doi.org\/10.1038\/sj.jidsymp.5650013","journal-title":"J Investig Dermatol Symp Proc"},{"key":"5068_CR15","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/S0140-6736(94)91819-8","volume":"344","author":"MR da Costa","year":"1994","unstructured":"da Costa\u00a0MR, Aniceto\u00a0C, Jesus\u00a0MF, Mendes\u00a0M (1994) Quick healing of leg ulcers after molgramostim. Lancet 344:481\u2013482. https:\/\/doi.org\/10.1016\/S0140-6736(94)91819-8","journal-title":"Lancet"},{"key":"5068_CR16","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/s0002-9610(97)89589-x","volume":"173","author":"MR da Costa","year":"1997","unstructured":"da Costa\u00a0MR, Jesus\u00a0FM, Aniceto\u00a0C, Mendes\u00a0M (1997) Double-blind randomized placebo-controlled trial of the use of granulocyte-macrophage colony-stimulating factor in chronic leg ulcers. Am J Surg 173:165\u2013168. https:\/\/doi.org\/10.1016\/s0002-9610(97)89589-x","journal-title":"Am J Surg"},{"key":"5068_CR17","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S0741-5214(99)70076-5","volume":"30","author":"WA Marston","year":"1999","unstructured":"Marston\u00a0WA, Carlin\u00a0RE, Passman\u00a0MA, Farber\u00a0MA, Keagy\u00a0BA (1999) Healing rates and cost efficacy of outpatient compression treatment for leg ulcers associated with venous insufficiency. J\u00a0Vasc Surg 30:491\u2013498. https:\/\/doi.org\/10.1016\/S0741-5214(99)70076-5","journal-title":"J Vasc Surg"},{"key":"5068_CR18","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S0094-1298(20)32468-8","volume":"25","author":"BC Nwomeh","year":"1998","unstructured":"Nwomeh\u00a0BC, Yager\u00a0DR, Cohen\u00a0IK (1998) Physiology of the chronic wound. Clin Plast Surg 25:341\u2013356","journal-title":"Clin Plast Surg"},{"key":"5068_CR19","doi-asserted-by":"publisher","first-page":"3S","DOI":"10.1016\/j.jvs.2014.04.049","volume":"60","author":"TF O\u2019Donnell","year":"2014","unstructured":"O\u2019Donnell\u00a0TF, Passman\u00a0MA, Marston\u00a0WA, Ennis\u00a0WJ, Dalsing\u00a0M, Kistner\u00a0RL, Lurie\u00a0F, Henke\u00a0PK, Gloviczki\u00a0ML, Ekl\u00f6f\u00a0BG, Stoughton\u00a0J, Raju\u00a0S, Shortell\u00a0CK, Raffetto\u00a0JD, Partsch\u00a0H, Pounds\u00a0LC, Cummings\u00a0ME, Gillespie\u00a0DL, McLafferty\u00a0RB, Murad\u00a0MH, Wakefield\u00a0TW, Gloviczki\u00a0P (2014) Management of venous leg ulcers: clinical practice guidelines of the Society for Vascular Surgery\u00ae and the American Venous Forum. J\u00a0Vasc Surg 60:3S\u201359S. https:\/\/doi.org\/10.1016\/j.jvs.2014.04.049","journal-title":"J Vasc Surg"},{"key":"5068_CR20","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1136\/bmj.39248.634977.AE","volume":"335","author":"S Palfreyman","year":"2007","unstructured":"Palfreyman\u00a0S, Nelson\u00a0EA, Michaels\u00a0JA (2007) Dressings for venous leg ulcers: systematic review and meta-analysis. BMJ 335:244. https:\/\/doi.org\/10.1136\/bmj.39248.634977.AE","journal-title":"BMJ"},{"key":"5068_CR21","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1177\/0268355516632998","volume":"31","author":"JD Raffetto","year":"2016","unstructured":"Raffetto\u00a0JD (2016) Pathophysiology of wound healing and alterations in venous leg ulcers-review. Phlebology 31:56\u201362. https:\/\/doi.org\/10.1177\/0268355516632998","journal-title":"Phlebology"},{"issue":"Suppl 2","key":"5068_CR22","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.1007\/BF01973601","volume":"13","author":"M Robson","year":"1994","unstructured":"Robson\u00a0M, Kucukcelebi\u00a0A, Carp\u00a0SS, Hayward\u00a0PG, Hui\u00a0PS, Cowan\u00a0WT, Ko\u00a0F, Cooper\u00a0DM (1994) Effects of granulocyte-macrophage colony-stimulating factor on wound contraction. Eur J Clin Microbiol Infect Dis 13(Suppl 2):S41\u2013S46. https:\/\/doi.org\/10.1007\/BF01973601","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"5068_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2021.10.026","author":"K Singh","year":"2021","unstructured":"Singh\u00a0K, Maity\u00a0P, Koroma\u00a0AK, Basu\u00a0A, Pandey\u00a0RK, Vander Beken\u00a0S, Haas\u00a0P, Krug\u00a0L, Hainzl\u00a0A, Sindrilaru\u00a0A, Pfeiffer\u00a0C, Wlaschek\u00a0M, Frank\u00a0NY, Frank\u00a0MH, Ganss\u00a0C, B\u00e1nv\u00f6lgyi\u00a0A, Wikonk\u00e1l\u00a0N, Eming\u00a0S, Pastar\u00a0I, Tomic-Canic\u00a0M, Kluth\u00a0MA, Scharffetter-Kochanek\u00a0K (2021) Angiogenin released from ABCB5+ Stromal precursors improves healing of diabetic wounds by promoting angiogenesis. J\u00a0Invest Dermatol. https:\/\/doi.org\/10.1016\/j.jid.2021.10.026","journal-title":"J Invest Dermatol"},{"key":"5068_CR24","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/193293a0","volume":"193","author":"GD Winter","year":"1962","unstructured":"Winter\u00a0GD (1962) Formation of the scab and the rate of epithelization of superficial wounds in the skin of the young domestic pig. Nature 193:293\u2013294. https:\/\/doi.org\/10.1038\/193293a0","journal-title":"Nature"},{"key":"5068_CR25","doi-asserted-by":"publisher","first-page":"e6881","DOI":"10.1097\/MD.0000000000006881","volume":"96","author":"D Yan","year":"2017","unstructured":"Yan\u00a0D, Liu\u00a0S, Zhao\u00a0X, Bian\u00a0H, Yao\u00a0X, Xing\u00a0J, Sun\u00a0W, Chen\u00a0X (2017) Recombinant human granulocyte macrophage colony stimulating factor in deep second-degree burn wound healing. Medicine 96:e6881. https:\/\/doi.org\/10.1097\/MD.0000000000006881","journal-title":"Medicine"},{"key":"5068_CR26","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.burns.2012.02.001","volume":"38","author":"H Yan","year":"2012","unstructured":"Yan\u00a0H, Chen\u00a0J, Peng\u00a0X (2012) Recombinant human granulocyte-macrophage colony-stimulating factor hydrogel promotes healing of deep partial thickness burn wounds. Burns 38:877\u2013881. https:\/\/doi.org\/10.1016\/j.burns.2012.02.001","journal-title":"Burns"},{"key":"5068_CR27","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1111\/j.1524-475X.2009.00526.x","volume":"17","author":"L Zhang","year":"2009","unstructured":"Zhang\u00a0L, Chen\u00a0J, Han\u00a0C (2009) A multicenter clinical trial of recombinant human GM-CSF hydrogel for the treatment of deep second-degree burns. Wound Repair Regen 17:685\u2013689. https:\/\/doi.org\/10.1111\/j.1524-475X.2009.00526.x","journal-title":"Wound Repair Regen"},{"key":"5068_CR28","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1111\/iwj.12313","volume":"13","author":"Y Zhang","year":"2016","unstructured":"Zhang\u00a0Y, Wang\u00a0T, He\u00a0J, Dong\u00a0J (2016) Growth factor therapy in patients with partial-thickness burns: a\u00a0systematic review and meta-analysis. Int Wound\u00a0J 13:354\u2013366. https:\/\/doi.org\/10.1111\/iwj.12313","journal-title":"Int Wound J"}],"container-title":["Die Dermatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-022-05068-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00105-022-05068-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-022-05068-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T11:12:21Z","timestamp":1673521941000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00105-022-05068-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,26]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["5068"],"URL":"https:\/\/doi.org\/10.1007\/s00105-022-05068-4","relation":{},"ISSN":["2731-7005","2731-7013"],"issn-type":[{"value":"2731-7005","type":"print"},{"value":"2731-7013","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,26]]},"assertion":[{"value":"22 September 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"E.\u00a0Jaschke, J.\u00a0Umlauft, K.\u00a0Palmer-Reichel, W.\u00a0Oberaigner und M.\u00a0Schmuth geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Alle beschriebenen Untersuchungen am Menschen oder an menschlichem Gewebe sowie die \u201eoff-label\u201c-Anwendung von GM-CSF wurden im Einklang mit nationalem Recht sowie gem\u00e4\u00df der Deklaration von Helsinki von 1975 (in der aktuellen, \u00fcberarbeiteten Fassung) durchgef\u00fchrt.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}